These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36781038)

  • 1. Development of systemic lupus erythematosus in patients with immune thrombocytopenic purpura: A systematic meta-analysis.
    Pamuk ON; Ali SM; Hasni S
    Autoimmun Rev; 2023 Apr; 22(4):103297. PubMed ID: 36781038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and risk factors of systemic lupus erythematosus in patients with primary immune thrombocytopenia: a systematic review and meta-analysis.
    Zhou EM; Shen H; Wang D; Xu W
    PeerJ; 2024; 12():e17152. PubMed ID: 38666084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors for the development of systemic lupus erythematosus in patients with immune thrombocytopenia.
    Ahn SM; Choi EJ; Oh JS; Kim YG; Lee CK; Yoo B; Hong S
    Arthritis Res Ther; 2022 Sep; 24(1):213. PubMed ID: 36068638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for future development of systemic lupus erythematosus in children with idiopathic thrombocytopenic purpura.
    Hazzan R; Mukamel M; Yacobovich J; Yaniv I; Tamary H
    Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):657-9. PubMed ID: 16933242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and clinical significance of elevated antinuclear antibody test in children and adult patients with idiopathic thrombocytopenic purpura.
    Altintas A; Ozel A; Okur N; Okur N; Cil T; Pasa S; Ayyildiz O
    J Thromb Thrombolysis; 2007 Oct; 24(2):163-8. PubMed ID: 17436144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential risk factors for the development from immune thrombocytopenia to systemic lupus erythematosus: a case-control study in Chinese children.
    Song Y; Zhang Y; Li Z; Liu J; Xiao J; Song H
    Ann Hematol; 2022 Jul; 101(7):1447-1456. PubMed ID: 35532821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a population-based cohort study.
    Zhu FX; Huang JY; Ye Z; Wen QQ; Wei JC
    Ann Rheum Dis; 2020 Jun; 79(6):793-799. PubMed ID: 32241798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical significance of antinuclear antibody in patients with idiopathic thrombocytopenic purpura].
    Kurata Y; Miyagawa S; Kosugi S; Kashiwagi H; Honda S; Mizutani H; Tomiyama Y; Kanayama Y; Matsuzawa Y
    Rinsho Ketsueki; 1992 Sep; 33(9):1178-82. PubMed ID: 1433939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-titer antinuclear antibodies, anti-SSA/Ro antibodies and anti-nuclear RNP antibodies in patients with idiopathic thrombocytopenic purpura.
    Kurata Y; Miyagawa S; Kosugi S; Kashiwagi H; Honda S; Mizutani H; Tomiyama Y; Kanayama Y; Matsuzawa Y
    Thromb Haemost; 1994 Feb; 71(2):184-7. PubMed ID: 8191396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune thrombocytopenia in systemic lupus erythematosus: Prevalence, risk factors, and a novel predictive model for risk assessment.
    Cornudella Lema J; Sánchez-González B; Carrión-Barberà I; Vázquez Montes de Oca S; García Pallarols F; Salman-Monte TC
    Med Clin (Barc); 2024 May; 162(10):461-469. PubMed ID: 38383267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.
    Khellaf M; Chabrol A; Mahevas M; Roudot-Thoraval F; Limal N; Languille L; Bierling P; Michel M; Godeau B
    Am J Hematol; 2014 Feb; 89(2):194-8. PubMed ID: 24254965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Childhood-onset systemic lupus erythematosus and immune thrombocytopenia: Prevalence and risk factors.
    Kittivisuit S; Vachvanichsanong P; McNeil E; Chotsampancharoen T
    Pediatr Blood Cancer; 2021 Aug; 68(8):e29146. PubMed ID: 34047041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment with belimumab for immune thrombocytopenia associated with systemic lupus erythematosus: A report of two cases.
    Nakayama K; Tamimoto Y; Nakayama T
    Mod Rheumatol Case Rep; 2023 Dec; 8(1):69-73. PubMed ID: 37718578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ANA-positive primary immune thrombocytopaenia: a different clinical entity with increased risk of connective tissue diseases.
    Liu Y; Chen S; Yang G; Wang B; Lan J; Dai F; Rao P; Wu P; Qian H; Shi G
    Lupus Sci Med; 2021 Oct; 8(1):. PubMed ID: 34610996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excellent response to treatment with hydroxychloroquine in pediatric patients with SLE-related immune thrombocytopenia.
    Brik-Simon D; Efros O; Levinsky Y; Amarilyo G; Tirosh I; Levy-Mendelovich S; Steinberg-Shemer O; Izraeli S; Yacobovich J; Gilad O
    Pediatr Blood Cancer; 2024 May; 71(5):e30911. PubMed ID: 38348516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of immune thrombocytopenia associated with autoimmune disease: A retrospective study.
    Liu Y; Chen S; Sun Y; Lin Q; Liao X; Zhang J; Luo J; Qian H; Duan L; Shi G
    Medicine (Baltimore); 2016 Dec; 95(50):e5565. PubMed ID: 27977588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of the antinuclear antibody test in selected children with idiopathic thrombocytopenic purpura.
    Zimmerman SA; Ware RE
    J Pediatr Hematol Oncol; 1997; 19(4):297-303. PubMed ID: 9256827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nine-year's follow up on the appearance of autoantibodies in a child with idiopathic thrombocytopenic purpura subsequently developing lupus with central nervous system manifestations].
    Kagitani M; Makino S; Kinjo Y; Hirano S; Tabushi Y; Sasaki M; Takeuchi T; Hanafusa T; Murata T
    Ryumachi; 2002 Jun; 42(3):591-6. PubMed ID: 12166113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of a patient with refractory immune thrombocytopenic purpura in systemic lupus erythematosus with rituximab.
    Abe K; Ishikawa Y; Ishikawa J; Fujiwara M; Kita Y
    Immunol Med; 2019 Dec; 42(4):185-188. PubMed ID: 31794352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab alleviates pediatric systemic lupus erythematosus associated refractory immune thrombocytopenia: a case-based review.
    Mu F; Bai X; Lou Y; Luo P; Guo Q
    Immunol Res; 2024 Jun; 72(3):503-511. PubMed ID: 38279058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.